Short description
Igenica is a biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer.
Description
Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, accelerating development and the delivery of effective therapies to patients.
Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products.
Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures.
Total funding
$$121212
Sign in for full access
Location
Burlingame, California, United States, North America
Founded on
January 1, 2009
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Nopepepe, Cannot Access, No Way, Noaccessforu, Noway Youcantaccess
Sign in for full access
Founders
Guoqing Chen, Robert D. Schreiber